Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions).
Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information.
The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation.
Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable.
You may not be if
Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment.
Prior treatment with rituximab.
Contraindications to ocrelizumab as per the local prescribing information.
Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes.
Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results.
For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.
Clareo Health | Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
